Vital Signs - Genetic Screening: Saving Time and Money


USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This issue of Vital Signs, released on October 2, 2006, provides a strategic overview and discussion of the potential impact of genetic screening in Alzheimer's therapy. Additionally, an emerging company profile is provided for The Medicines Company, a company that specializes in providing and developing pharmacutical products for the acute care hospital setting. Reimbursement and regulatory news from the FDA and CMS is also provided for the week of September 18 - September 22, 2006.

Table of Contents

Vital Signs - Genetic Screening: Saving Time and MoneyVital Signs: 2 October 2006This week's issue:

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.